Isotechnika Pharma Inc. (ISA.TO) Receives Additional Funding From the Government of Canada for the Preclinical Development of NICAM 440-02 as an Anti-Hepatitis C Agent
6/18/2013 8:55:39 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
EDMONTON, Alberta, June 18, 2013 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") today announced that it has received additional funding from the National Research Council Industrial Research Assistance Program ("NRC-IRAP") for its Non-Immunosuppressive Cyclophilin Antagonist Molecules ("NICAMs") program.
Help employers find you! Check out all the jobs and post your resume.
comments powered by